{
    "Trade/Device Name(s)": [
        "Contour\u00ae next GEN Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Ascensia Diabetes Care",
    "510(k) Number": "K193407",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160682"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "November 12, 2020",
    "Summary Letter Received Date": "November 13, 2020",
    "Submission Date": "December 22, 2021",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood (fingerstick)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Contour\u00ae next GEN meter",
        "Contour\u00ae Diabetes app"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical detection",
        "Bluetooth Low Energy communication"
    ],
    "Methodologies": [
        "Blood glucose measurement"
    ],
    "Submission Type(s)": [
        "Analyzer",
        "System",
        "Reagent",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for the Contour\u00ae next GEN Blood Glucose Monitoring System with Bluetooth connectivity and quantitative glucose measurement in capillary blood.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from the fingertip, for self-testing by people with diabetes at home as an aid in monitoring the effectiveness of a diabetes control program; not for diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}